Published February 24, 2022 | Version v1
Other Open

Treating non-small cell lung cancer: What do patients PREFER

  • 1. Alexion
  • 2. European Institute of Oncology
  • 1. KU Leuven
  • 2. University Medical Centre Utrecht
  • 3. European Cancer Patient Coalition
  • 4. Erasmus University Rotterdam
  • 5. European Institute of Oncology


We wanted to learn about lung cancer patients’ preferences for new treaments, and what they considered to be the maximum acceptable risk, and the minimum acceptable benefit of a treatment.


Treating non-small cell lung cancer - What do patients PREFER.pdf

Files (795.4 kB)

Additional details


PREFER – Patient Preferences in benefit risk assessments during the drug life cycle - Sofia ref.: 115966 115966
European Commission